Juno Therapeutics Priced, Nasdaq: JUNO
Developing T-cell therapies for lymphomas, leukemias and other cancers.
Industry: Health Care
First Day Return: +45.8%
JUNO
Developing T-cell therapies for lymphomas, leukemias and other cancers.
| IPO Data | |
|---|---|
| IPO Date | 12/18/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $265 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Seattle, WA, United States |
| Founded | 2013 |
| Employees at IPO | 70 |
| Website www.junotherapeutics.com | |
IPO News for Juno Therapeutics
Juno Therapeutics (JUNO) Performance
